Novel algorithm including CA-125, HE4 and body mass index in the diagnosis of endometrial cancer

Gynecologic Oncology

Volumn 147, Issue 1, 2017, Pages 126-132

  Knific, Tamara ^a   Osredkar, Joško ^b   Smrkolj, Špela ^b   Tonin, Irena ^b   Vouk, Katja ^a   Blejec, Andrej ^c   Frković Grazio, Snježana ^b   Rižner, Tea Lanišnik ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^c NATIONAL INSTITUTE OF BIOLOGY   (Slovenia)

Author keywords

Algorithm; Biomarkers; CA 125; Endometrial cancer; HE4; Logistic regression; Prognosis

Indexed keywords

CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; PROTEIN; TUMOR MARKER; WFDC2 PROTEIN, HUMAN;

ADULT; AGED; ALGORITHM; ARTICLE; BODY MASS; CANCER PROGNOSIS; CANCER SURVIVAL; CASE CONTROL STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ELECTROCHEMILUMINESCENCE; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; LOW RISK PATIENT; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MYOMETRIUM; OVARY METASTASIS; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; TUMOR INVASION; AREA UNDER THE CURVE; BLOOD; ENDOMETRIAL NEOPLASMS; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; ALGORITHMS; AREA UNDER CURVE; BIOMARKERS, TUMOR; BODY MASS INDEX; CA-125 ANTIGEN; CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEINS; SENSITIVITY AND SPECIFICITY;

EID: 85025175181     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2017.07.130     Document Type: Article

References (36)

1. Cancer in Slovenia, Epidemiology and Cancer Registry. 2016, 2012, Institute of Oncology Ljubljana, Ljubljana: Ljubljana, 2012.
2. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136 (2015), E359–86.
3. Sonoda, Y., Barakat, R.R., Screening and the prevention of gynecologic cancer: endometrial cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 20 (2006), 363–377.
4. Hampel, H., de la Chapelle, A., The search for unaffected individuals with Lynch syndrome: do the ends justify the means?. Cancer Prev. Res. (Phila.) 4 (2011), 1–5.
5. Morice, P., Leary, A., Creutzberg, C., Abu-Rustum, N., Darai, E., Endometrial cancer. Lancet 387 (2016), 1094–1108.
6. Bogani, G., Dowdy, S.C., Cliby, W.A., Ghezzi, F., Rossetti, D., Mariani, A., Role of pelvic and para-aortic lymphadenectomy in endometrial cancer: current evidence. J. Obstet. Gynaecol. Res. 40 (2014), 301–311.
7. Creasman, W.T., Morrow, C.P., Bundy, B.N., Homesley, H.D., Graham, J.E., Heller, P.B., Surgical pathologic spread patterns of endometrial cancer. A gynecologic oncology group study. Cancer 60 (1987), 2035–2041.
8. Capriglione, S., Plotti, F., Miranda, A., Ricciardi, R., Scaletta, G., Aloisi, A., et al. Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a single-center controlled study. Tumour Biol. 36 (2015), 4151–4156.
9. Werner, H.M., Salvesen, H.B., Current status of molecular biomarkers in endometrial cancer. Curr. Oncol. Rep., 16, 2014, 403.
10. Dobrzycka, B., Mackowiak-Matejczyk, B., Terlikowska, K.M., Kinalski, M., Terlikowski, S.J., Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy. Adv. Med. Sci. 61 (2016), 23–27.
11. Haldorsen, I.S., Salvesen, H.B., What is the best preoperative imaging for endometrial cancer?. Curr. Oncol. Rep., 18, 2016, 25.
12. Mutz-Dehbalaie, I., Egle, D., Fessler, S., Hubalek, M., Fiegl, H., Marth, C., et al. HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol. Oncol. 126 (2012), 186–191.
13. Rizner, T.L., Discovery of biomarkers for endometrial cancer: current status and prospects. Expert. Rev. Mol. Diagn. 16 (2016), 1315–1336.
14. Zamani, N., Modares Gilani, M., Zamani, F., Zamani, M.H., Utility of pelvic MRI and tumor markers HE4 and CA125 to predict depth of myometrial invasion and cervical involvement in endometrial cancer. J Family Reprod Health 9 (2015), 177–183.
15. Niloff, J.M., Klug, T.L., Schaetzl, E., Zurawski, V.R. Jr., Knapp, R.C., Bast, R.C. Jr., Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am. J. Obstet. Gynecol. 148 (1984), 1057–1058.
16. Kim, B.W., Jeon, Y.E., Cho, H., Nam, E.J., Kim, S.W., Kim, S., et al. Pre-treatment diagnosis of endometrial cancer through a combination of CA125 and multiplication of neutrophil and monocyte. J. Obstet. Gynaecol. Res. 38 (2012), 48–56.
17. Nicklin, J., Janda, M., Gebski, V., Jobling, T., Land, R., Manolitsas, T., et al. The utility of serum CA-125 in predicting extra-uterine disease in apparent early-stage endometrial cancer. Int. J. Cancer 131 (2012), 885–890.
18. Chen, Y.L., Huang, C.Y., Chien, T.Y., Huang, S.H., Wu, C.J., Ho, C.M., Value of pre-operative serum CA125 level for prediction of prognosis in patients with endometrial cancer. Aust. N. Z. J. Obstet. Gynaecol. 51 (2011), 397–402.
19. Drapkin, R., von Horsten, H.H., Lin, Y., Mok, S.C., Crum, C.P., Welch, W.R., et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 65 (2005), 2162–2169.
20. Moore, R.G., Brown, A.K., Miller, M.C., Badgwell, D., Lu, Z., Allard, W.J., et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol. Oncol. 110 (2008), 196–201.
21. Bignotti, E., Ragnoli, M., Zanotti, L., Calza, S., Falchetti, M., Lonardi, S., et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br. J. Cancer 104 (2011), 1418–1425.
22. Zanotti, L., Bignotti, E., Calza, S., Bandiera, E., Ruggeri, G., Galli, C., et al. Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome. Clin. Chem. Lab. Med. 50 (2012), 2189–2198.
23. Antonsen, S.L., Hogdall, E., Christensen, I.J., Lydolph, M., Tabor, A., Loft Jakobsen, A., et al. HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET). Acta Obstet. Gynecol. Scand. 92 (2013), 1313–1322.
24. Omer, B., Genc, S., Takmaz, O., Dirican, A., Kusku-Kiraz, Z., Berkman, S., et al. The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients. Tumour Biol. 34 (2013), 2645–2650.
25. Trabert, B., Wentzensen, N., Felix, A.S., Yang, H.P., Sherman, M.E., Brinton, L.A., Metabolic syndrome and risk of endometrial cancer in the united states: a study in the SEER-medicare linked database. Cancer Epidemiol. Biomark. Prev. 24 (2015), 261–267.
26. Lu, K.H., Dinh, M., Kohlmann, W., Watson, P., Green, J., Syngal, S., et al. Gynecologic cancer as a “sentinel cancer” for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet. Gynecol. 105 (2005), 569–574.
27. Saarelainen, S.K., Peltonen, N., Lehtimaki, T., Perheentupa, A., Vuento, M.H., Maenpaa, J.U., Predictive value of serum human epididymis protein 4 and cancer antigen 125 concentrations in endometrial carcinoma. Am. J. Obstet. Gynecol. 209:142 (2013), e1–6.
28. Chao, A., Tang, Y.H., Lai, C.H., Chang, C.J., Chang, S.C., Wu, T.I., et al. Potential of an age-stratified CA125 cut-off value to improve the prognostic classification of patients with endometrial cancer. Gynecol. Oncol. 129 (2013), 500–504.
29. Goksedef, B.P., Gorgen, H., Baran, S.Y., Api, M., Cetin, A., Preoperative serum CA 125 level as a predictor for metastasis and survival in endometrioid endometrial cancer. J. Obstet. Gynaecol. Can. 33 (2011), 844–850.
30. Myriokefalitaki, E., Vorgias, G., Vlahos, G., Rodolakis, A., Prognostic value of preoperative Ca125 and Tag72 serum levels and their correlation to disease relapse and survival in endometrial cancer. Arch. Gynecol. Obstet. 292 (2015), 647–654.
31. Baser, E., Gungor, T., Togrul, C., Turkoglu, O., Celen, S., Preoperative prediction of poor prognostic parameters and adjuvant treatment in women with pure endometrioid type endometrial cancer: what is the significance of tumor markers?. Eur. J. Gynaecol. Oncol. 35 (2014), 513–518.
32. Presl, J., Novotny, Z., Topolcan, O., Vlasak, P., Kucera, R., Fuchsova, R., et al. CA125 and HE4 levels in a Czech female population diagnosed with endometrial cancer in preoperative management. Anticancer Res. 34 (2014), 327–331.
33. Brennan, D.J., Hackethal, A., Metcalf, A.M., Coward, J., Ferguson, K., Oehler, M.K., et al. Serum HE4 as a prognostic marker in endometrial cancer—a population based study. Gynecol. Oncol. 132 (2014), 159–165.
34. Moore, R.G., Miller, C.M., Brown, A.K., Robison, K., Steinhoff, M., Lambert-Messerlian, G., Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus. Int. J. Gynecol. Cancer 21 (2011), 1185–1190.
35. Prueksaritanond, N., Cheanpracha, P., Yanaranop, M., Association of serum HE4 with primary tumor diameter and depth of myometrial invasion in endometrial cancer patients at Rajavithi hospital. Asian Pac. J. Cancer Prev. 17 (2016), 1489–1492.
36. Brennan, D.J., Hackethal, A., Mann, K.P., Mutz-Dehbalaie, I., Fiegl, H., Marth, C., et al. Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance. BMC Cancer, 15, 2015, 33.